BACKGROUND: Diminished use and worse outcomes after immediate breast reconstruction (IBR) have been documented for Medicaid beneficiaries. However, to the authors' knowledge, the contribution of patient clustering at hospitals with a high percentage of Medicaid patients to these inequalities in IBR delivery is unknown. METHODS: A cross-sectional analysis of patients undergoing IBR after mastectomy using the 2007 to 2011 Nationwide Inpatient Sample database was performed. Hospital Medicaid status was calculated as the percentage of all patients with Medicaid as a primary payer. Tertile groupings were generated to enable statistical analysis. Hierarchical regression models were used to investigate the link between Medicaid status and IBR use, outcomes, and costs. A subgroup of patients undergoing IBR for noninvasive cancer or those with increased genetic risk were used to study IBR use. RESULTS: A total of 30,086 IBR cases in 1199 hospitals were analyzed. Hierarchical regression analysis demonstrated an association between high Medicaid burden hospitals and significantly decreased odds of IBR among patients with in situ disease and/or an elevated risk of cancer (odds ratio, 0.64; 95% confidence interval [95% CI], 0.507-0.806). Increasing age, obesity, being nonwhite, having more comorbid conditions, and having government insurance were found to be associated with diminished odds of IBR (P<.001 in all instances). In-hospital surgical and medical complication rates were comparable across the 3 strata of hospital Medicaid status. Log-adjusted costs of care were found to be positively associated with a higher hospital Medicaid burden status (coefficient of 0. 
INTRODUCTION
In recent years, Medicaid insurance status has been identified as an independent risk factor for diminished access to immediate breast reconstruction (IBR) 1, 2 and poor outcomes after mastectomy. 1, 3, 4 This is important because IBR offers clear psychosocial benefits to recipients (eg, improved body image and self-esteem). 5, 6 These issues also have considerable health policy salience because: 1) Medicaid currently is the largest health insurance program, by enrollment, in the United States 7 ; and 2) Medicaid expansion was one of the principal vectors for increasing insurance coverage under the Patient Protection and Affordable Care Act.
Health insurance is just one factor among many in a complex relationship among health care access, quality, and outcomes. 8 Other components of this conceptual framework include health behaviors, the availability of social support, and health care system characteristics. 8, 9 Thus, Medicaid payer status alone cannot explain disparities in health care access and outcomes. Hospital-level characteristics such as payer mix and annual volume have been shown to influence the quality 10, 11 and clinical outcomes 12 of oncologic care. A 2002 Institute of Medicine report described how patterns of care delivery in hospitals that served many Medicaid beneficiaries were sharply different from those of hospitals that served largely Medicare or privately insured patients. 13, 14 Lower reimbursement levels and limited resources at high Medicaid burden hospitals (HMHs) were identified as the principal drivers of this discrepancy. 13, 14 For Medicaid beneficiaries with colon cancer, HMHs deliver demonstrably lower quality care. 10, 13 This raises the question as to whether noted disparities in IBR use and outcomes (complications and cost) are produced by the processes and quality of breast cancer care delivery at HMHs (ie, hospital characteristics) and not patient-level factors. In other words, do Medicaid beneficiaries endure IBR disparities because they pursue treatment, or "cluster," at HMHs? A recent study demonstrated that female patients in the lowest tertile of Medicaid hospitals (low Medicaid burden hospitals [LMHs]) had 89% higher odds of undergoing IBR compared with their HMH counterparts. 15 However, these results are highly susceptible to confounding from the lack of clinical cancer stage information in the National Inpatient Sample (NIS) database and the fact that Medicaid patients have more locally advanced cancers at the time of their initial presentation. [16] [17] [18] This is important because disease stage is one of the most significant clinical predictors of IBR use. 19 Reasons include concerns regarding delaying the onset of adjuvant therapy due to IBR-related complications and a higher likelihood of needing postoperative radiotherapy, which might compromise esthetic outcomes 20 and increase complication rates. 21, 22 The objective of the current study was to unpack the impact of hospital Medicaid status on the delivery of IBR along the dimensions of use, complications, and total costs of care. Although evidence in the literature is mixed, the results of a recent study demonstrated that after major surgery, the HMH care setting was associated with increased total costs and risk of surgical complications. 23 An enriched understanding of the effect of hospital factors on IBR delivery might lead to the development of quality improvement strategies targeted at HMHs in an effort to improve the overall quality of IBR care, 10 should these hospitals be found to have inferior performance.
MATERIALS AND METHODS

Data Source
We used the 2007 to 2011 NIS database to perform a cross-sectional analysis of patients undergoing total mastectomy. The NIS, furnished by the Agency for Healthcare Research and Quality, is the largest collection of all-payer, inpatient administrative data in the United States. 24, 25 Information captured in the NIS database is well described, 24 and multiple studies have used it to investigate hospital-level variations in surgical outcomes, 24, 26 We identified the following hospital-level characteristics in the NIS database: bed size (small, medium, or large), teaching status, rural versus urban location, participation in a multihospital system, census region (Northeast, Midwest/North-Central, South, or West), and ownership structure (public, private nonprofit, or private investor-owned). Tertiles (low, medium, and high) also were created for annual hospital-specific volumes for IBR.
Patient Selection
We used International Classification of Diseases, Ninth Revision (ICD-9) diagnosis and procedure codes to identify adult (aged >18 years) patients who underwent total mastectomy and IBR over the study period (2007) (2008) (2009) (2010) (2011) for any of the following 3 mutually inclusive indications: 1) diagnosis of breast cancer (ICD-9 codes 174.0-174.9); 2) increased risk of breast cancer due to genetic susceptibility or family history (ICD-9 codes v16.3, v10.3, and v84.01); and 3) ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) (ICD-9 code 233.0 for both). A hierarchy was applied in situations in which multiple indications were attributed to a mastectomy (ie, a cancer diagnosis > DCIS/LCIS > cancer predisposition). Male patients, emergency procedures, or breast reconstruction without a concomitant mastectomy (ie, delayed reconstruction) were excluded from analysis. These exclusions were applied to create a clinically homogenous sample of patients undergoing elective procedures. All ICD-9 procedure codes used for study sample creation have been published previously. 29 We extracted the following demographic information for the current study: age, race (white, black, Hispanic, or Asian), obesity (presence of ICD-9 codes 278.0, 278.00, 278.01, 278.02, or 278.03), and primary insurance status (Medicare, Medicaid, private, or self-pay/ other). Patient comorbidities, defined as coexisting medical conditions not related to the indication for mastectomy, were identified using ICD-9 codes and were used to compute a Charlson Comorbidity Index (CCI) score. 30 The CCI scores then were stratified into the following groups for statistical analysis: 1, 2, or >3. Median household income for the patient's zip code is available in the NIS database as a categorical variable, which we labeled as "lowest," "low," "high," and "highest" according to quartiles. Discharge disposition (routine, rehabilitation center, home health aide, and skilled nursing facility) also was reported in the NIS database.
Outcomes of Interest
For analysis, our primary outcomes of interest (dependent variables) were receipt of IBR, total inpatient costs, and rates of medical and surgical complications after IBR. With regard to our examination of the receipt of IBR across Medicaid hospital status, we mitigated any aforementioned confounding (lack of cancer stage information in the NIS data set) by calculating the IBR rates only for patients with an increased risk of breast cancer and/or in situ disease (ie, prophylactic IBR and IBR for noninvasive cancer, respectively). In other words, the study cohort (ie, denominator) for the current analysis was those patients undergoing mastectomy for in situ disease (DCIS/LCIS) or because of an increased cancer risk. These patients either are stage 0 (DCIS/LCIS) or without any cancer (prophylactic IBR for family history or genetic predisposition), thereby circumventing the unavailability of clinical stage information in the NIS database. More importantly, these patients are significantly more likely to receive IBR 15, 19, 31 compared with patients with invasive cancer, and often are considered to be appropriate candidates for IBR.
We derived complications from codes for acute events assigned at the time of hospital discharge (ie, inpatient complications). 24 Medical complications include pulmonary complications, renal failure, urinary tract infection, stroke, deep venous thrombosis/pulmonary embolism, and cardiac events. 24 Surgical complications included flap revision, surgical site infection, wound dehiscence, hematoma/seroma, bleeding, postoperative shock, microvascular anastomotic complications, and blood transfusion. 32 Supporting Information Table 1 outlines the ICD-9 codes used to create the categories of medical and surgical complications. Total facility charges related to the index hospital admission were converted to costs using hospital year-specific cost-to-charge ratios (CCRs). CCRs are based on accounting reports made available by the Centers for Medicare and Medicaid Services. The NIS provides the CCR as a free supplemental file. It contains hospital-specific CCRs that are based on all-payer inpatient costs for nearly every hospital in the NIS database. Although the NIS CCRs are an approximate, they are publicly available and remain one of the most common methods for estimating payments after surgical procedures. 33, 34 All costs were adjusted for inflation to 2016 US dollars and then log-transformed for risk adjustment because of a non-Gaussian distribution (ie, right skewed). The analytic cohort (ie, denominator) used for analysis of complications and inpatient costs was all IBR patients. Because these patients would have had to have undergone a mastectomy in the first place, all possible indications for mastectomy were used to create this analytic sample (ie, invasive cancer, DCIS/LCIS, and family history/genetic predisposition).
Statistical Analysis
We aggregated descriptive information to the level of hospital Medicaid status (LMH, MMH, and HMH). We compared frequency distributions between variables using the chi-square test or one-way analysis of variance, as indicated. We performed hierarchical regression analysis to adjust for clustering of patients with similar characteristics within hospitals and to model our 4 outcomes of interest: IBR receipt, medical complications, surgical complications, and log costs. Mixed-effect logistic regression was used for binary outcomes and mixed-effect linear regression was used for log costs. For both models, we used the individual hospital identification as a random intercept and adjusted for covariates, including patient demographics, socioeconomic status, comorbid conditions, hospital characteristics, and hospital Medicaid status. Finally, we developed a separate multivariate logistic regression (fixed-effects) model to discern which hospitallevel characteristics are associated with HMH status.
All tests were 2-sided, and P values <.05 were established as statistically significant. We used STATA statistical software (version 14; StataCorp LP, College Station, Texas) to perform all analysis. The institutional review board at Johns Hopkins University Hospital in Baltimore, Maryland approved the study.
RESULTS
Descriptive Statistics Regarding IBR Patients
There were 30,086 IBR cases across 1199 hospitals that met inclusion criteria over the study period. HMHs comprised 35% of all hospitals whereas LMHs encompassed 24.5% of hospitals. The majority of IBR recipients were white (77.9%), nonobese (94.2%), privately insured (79.7%), and had 2 comorbidities (P.001). The mean Original Article patient age was 51.13 6 10.46 years. In HMHs, we observed the greatest representation of black/Hispanic (21.65%), obese (6.75%), and lowest income patients (19.22%). The highest percentage of governmentsubsidized health plan enrollees (ie, Medicare or Medicaid) was found in the HMH setting (21.84%).
On unadjusted analysis, a HMH was most likely to have a low annual volume of IBR (37.28%), to be an urban-teaching designation (74.53%), to be a public entity (14.75%), and to have a large bed size (76.04%). Complete results are shown in Tables 1 and 2 .
Unadjusted IBR Receipt, In-Hospital Complications, and Costs of Care There were 13,633 patients who underwent IBR for noninvasive cancer (ie, DCIS/LCIS) or increased genetic predisposition. The overall IBR rate for this cohort was 63.99%, and LMHs were observed to have the highest unadjusted IBR rates (69.64%) compared with MMHs (63.46%) and HMHs (59.15%) (P<.001) ( Table 3 ). In situ disease was the more common indication for this cohort of patients (70.42%).
HMHs had the highest unadjusted rate of surgical complications (7.17%) compared with MMHs (5.82%) and LMHs (5.78%) (P<.001). We observed an analogous (Table 6) .
MMHs (OR, .0038) and HMHs (OR, .053) [P 5 .007 in both instances] had higher log costs for the index IBR hospitalization compared with LMHs. There also was a positive association noted between log costs and annual IBR volume (intermediate: OR, .034; P 5 .024 and high: OR, .164; P < .001), obesity (OR, .075; P < .001), and having >3 comorbidities (OR, .0182; P 5 .006). Patients who were black (OR, 2.021; P 5 .026) or Asian (OR, 2.066; P < .001) and Medicare beneficiaries (OR, 2.042; P < .001) were found to have lower log costs (Table 7) .
Supporting Information Table 2 shows the complete results of a fixed regression analysis that examined hospital-level characteristics associated with HMH status. In summary, HMH status was significantly associated with public ownership, large bed size, participation in a multihospital system, being an urban-teaching institution and a North-Central or Midwest US census region location.
DISCUSSION
The findings of the current study demonstrate that a HMH status is independently associated with diminished rates of IBR among appropriate surgical candidates and Original Article increased total costs of inpatient care. These findings are consistent with the existing literature, in which the attributes of safety-net institutions such as HMHs translate into less comprehensive and costlier care delivery. 15, 23 Examples of these features include inadequate staffing and limited financial resources. 23 Safety-net hospitals are institutions that provide a considerable amount of health care and related services to a payer mix that is predominated by Medicaid-insured, uninsured, and vulnerable patients. 35 Equivocal clinical outcomes across the 3 levels of Medicaid status were also observed in the current analysis. This is consistent with prior studies that have shown competitive care quality (ie, noninferior) for patients undergoing reconstructive surgery for hand trauma 36 and head and neck cancer. 24 The finding of diminished IBR use with HMH status is undoubtedly the result of a complex interplay of patient-level, organizational-level, and policy-level factors. At the policy level, prior research has suggested reduced Medicaid physician reimbursement rates compared with Medicare and commercial payers as a cause of lower access for Medicaid enrollees. 37 This issue becomes more pronounced during health care encounters that involve a surgical specialist. [38] [39] [40] Economic incentives are acknowledged to be a powerful determinant of physician behavior. 41 Consequently, it is possible that this discrepancy in physician reimbursement rates 42 might cause plastic surgeons to restrict the accessibility of their practice (ie, provision of IBR) in HMHs. In its current form, Medicaid financing does offer participating states some flexibility with regard to how participating physicians are reimbursed, with the overarching aim of optimizing health care access for beneficiaries. 43 Although remuneration parity with Medicare and commercial payers is not feasible, increasing reimbursement rates to levels that encourage the enlistment of an array of care providers such as plastic surgeons will considerably improve disparities in IBR use.
In a recent study, organization-level characteristics such as available staffing, system inefficiencies, and limited abilities to invest in care improvement activities were identified as potential drivers of the delivery of higher cost, lower quality care. 23 HMHs, which tend to be situated in very competitive health care markets (ie, urban settings), might try to increase revenue from nonMedicaid payers or not offer certain service lines such as IBR in an effort to contain costs/overhead. 23, 44 Any attempt to increase the equity of IBR delivery to the patients at HMHs would require these financially strained organizations to divert a considerable amount of institutional resources. 45 This is because IBR is very resourceintensive service line: it requires expensive devices (implants, operating microscopes), highly trained specialists, and protracted operating room use. 15 Effective next year, there will be a reduction in funding for Disproportionate Share Hospitals (DSH) 23, 46 in states that underwent Medicaid expansion under the Patient Protection and Affordable Care Act. This will threaten the solvency of HMHs and set in motion an unintended consequence of worsening inequities in IBR delivery. Conversely, we believe that an increase in resource allocation to HMHs is needed to allow them to realign their organizational features and deliver comprehensive, high-quality care.
Although we included several patient-level characteristics in the current analysis, there are other variables that are correlated with Medicaid eligibility but not routinely captured in administrative data sets. These variables, including educational level, health literacy, cultural attitudes toward IBR, and social support, also influence health care use. 8, 45, 47 The inclusion of these characteristics in our risk adjustment would improve our understanding of core population differences, 8 and generate a fairer assessment of the contribution of HMHs toward disparities in IBR delivery.
Adverse clinical events (surgical and medical complications) were low overall and found to not vary by hospital Medicaid status, after adjusting for patient characteristics, hospital-level features, and annual case volume. This represents a sharp divergence from the existing literature regarding the quality of care delivered in safety-net hospitals. 10, 13, 23, 24 We surmise that because IBR is an elective procedure, the surgical fitness of recipients is likely to be uniformly higher than that of other patients with cancer pursuing surgical treatment. In this situation, any patient who is a poor operative candidate is likely to be offered delayed breast reconstruction after a period of medical optimization or no reconstruction at all. Furthermore, because the NIS database only captures the complications that are detected during the index hospitalization, it is likely that the results of the current study are an underrepresentation of true complications that present in the outpatient setting or result in a hospital readmission. However, our observed rates of systemic and surgeryspecific complications are comparable to those of other large population-based studies. Using the 2005 to 2010 American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database (16,063 cases), Fischer et al in a 2014 study reported surgical and medical complication rates of 8.4% and 1.6%, respectively. 48 Most importantly, the current study results might be a reflection of the fact that HMHs are indeed able to deliver excellent clinical care for this population of surgical patients. The patient-level (obesity, age, comorbidities, insurance type, income, and race) and hospitallevel (teaching status, location, and annual volume) characteristics associated with IBR receipt and clinical outcomes in the current study also are consistent with the existing literature. 1, 16, 40, [49] [50] [51] [52] However, the current study has a few limitations that must be acknowledged. First, it is bound by a retrospective design, which is associated with an inherent selection bias and also limits our ability to determine causality. Second, being an administrative data set, the NIS is susceptible to errors/variations in coding practices and data abstraction. However both of these shortcomings are universally recognized and minimized by the strict annual validation (internal and external) of the NIS database. 53 Third, and as stated above, we were able to risk-adjust only the patient-level and hospital-level characteristics included in the NIS database. Examples of important covariates not currently captured in the data set include the availability of a staff plastic surgeon at a given hospital, patient preferences regarding breast reconstruction, and average patient wait times for IBR. Finally, it is likely that there are residual differences in patient comorbidity between treatment hospitals that impact the exposureoutcome relationship, despite our use of a hierarchical model. 54 Despite these limitations, we believe that the results of the current study constitute a meaningful contribution to the ongoing discussion regarding how best to deliver care to the most vulnerable factions of our population.
Conclusions
In the current study, HMHs were found to be associated with reduced IBR use and higher costs of care. The quality of surgical care delivery at HMHs, denoted by complication rates, was comparable to those of both LMHs and MMHs. HMHs, frequently pillars of the community, play a key role in our ability to care for disadvantaged patients and will continue to do so for the foreseeable future. 54 With this in mind, they must be a critical component of any and all efforts to reduce health care disparities. 54 Policy interventions that go beyond increasing insurance coverage, particularly Medicaid, and offer structural and financial assistance to HMHs are needed. Only then will we be able to meaningfully reduce the inequities in the delivery of breast cancer care.
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